Radiotherapeutic agents

Chromic Phosphate P 32. Chromic phosphate P. 1 Phosphocol P32. Cr -P04, is supplied as a suspension in II-mL vials containing NaCI and NaOAc in water with 5 benzyl alcohol. The radioactivity is II mCi, with concentn-don up to 1 mCi/mL. The usual dose is 10 to 20mCi inirapn 

Chromic phoiiphate is used for intracavitary instillation to educe effusions caused by metastatic disea.se. It decays by mission, with a half-life of 14.. days. Adverse reactions include transitory radiation sickness, bone marrow depre.s-sion. pleuriti.s, peritonitis, nausea, and abdominal cramping. 

Sodium Phosphate P 32. Sodium phosphate P 32. sodium radiophosphate, is supplied as an aqueous solution of a mixture of NaH2 P04 and Na2H P04 with a pH range ofS.O to 6.0. It contains S mCi/vial (0.67 mCi/mL) of radio-xtivity. expressed as a pure /3-emitter with a half-life of 14.3 days. Sodium phosphate P 32 is indicated for treatment of polycythemia vera. chronic myelocytic leukemia, and CLL Depression of leukocytes and platelets requires monitoring of blood and bone marrow at regular intervals. 

Sodium iodide 1131. Sodium iodide 1131. sodium radioiodide ( - I), lodotope. Theriodide. is. supplied in cap-. ules for oral use. or in aqueous solution for oral or parenteral uw. lodotope capsules contain I to SO mCi. and lodotope oral solutions contain 7.0S mCi/mL. Sodium iodide I 131 capsules contain 0.7 to l(K) mCi. and. sodium iodide oral alulion.s. 3.5 to ISO mCi/vial. Stock solutions ate prepared by dilution with Purified Water containing 0.2% sodium thiosulfate as a reducing agent. The dose is individualized I nr each patient. 

Sodium iodide I 131 is used for palliation in selected cases of thyroid carcinoma. The usual toxic effect is radiation sick-rzu. 

---

Cobalt-60, an artificial isotope, is an important gamma ray source, and is extensively used as a tracer and a radiotherapeutic agent. 

This reaction offers the advantage of a superior neutron yield of in a thermal reactor system. The abiHty to breed fissile from naturally occurring Th allows the world s thorium reserves to be added to its uranium reserves as a potential source of fission power. However, the Th/ U cycle is unlikely to be developed in the 1990s owing both to the more advanced state of the / Pu cycle and to the avadabiHty of uranium. Thorium is also used in the production of the cx-emitting radiotherapeutic agent, Bi, via the production of Th and subsequent decay through Ac (20). 

Hartman KB, Hamlin DK, Wilbur DS, Wilson LJ (2007) 211AtCl US-tube nanocapsules a new concept in radiotherapeutic-agent design. Small 3 1496-1499. 

Bismuth (Z = 83) is the heaviest stable element in group 15 (VA) of the periodic table (see Periodic Table Trends in the Properties of the Elements). The Bi isotope, which is 100% abundant, has a 9/2 nuclear spin. Bi, an alpha emitter is used in nuclear medicine as a radiotherapeutic agent. Bismuth has two stable oxidation states Bi(V), corresponding to complete loss of the valence electrons, and Bi(III), a lower oxidation state that retains two valence electrons. Both oxidation states are diamagnetic. The latter is more stable and more common since Bi(V) has a large reduction potential ... 

As part of the coordinated research project (CRP) on comparative evaluation of therapeutic radiopharmaceuticals, the ior-CEAl-(scFv)2 fragment and the somatostatin peptide analogues ior-P1394 and [DOTA,Tyr ]octreotate (DOTATATE) were evaluated as targeted agents. The results obtained from in vitro and in vivo studies deomonstrate the clinical usefulness of these radiolabelled biomolecules as radiotherapeutic agents. 

The present studies were aimed at the development of laboratory evaluation techniques for studying the efficacy of therapeutic radiopharmaceuticals. The primary goal was to develop radiotherapeutic agents using the peptide-BFCA conjugate DOTA-Tyr -octreotate (DOTATATE). The radioisotopes used for the therapeutic preparations were Lu and °Y. Lutetium-177 was identified as an ideal radionuclide for... 

For Lu-DOTATATE, multiple dose therapy is more effective than single dose therapy, since a decrease of the tumour proliferation index was observed. The data obtained suggest that optimizing the time interval for multiple dose regimens leads to increases in the therapeutic efficacy. These data show that Lu-DOTATATE could be an effective targeted radiotherapeutic agent. 

BANERJEE, S., et al., Au estradiol-conjugate for radiolabelling with Lu An attempt to prepare a radiotherapeutic agent, Biorg. Med. Chem. 13 (2005) 4315 322. 

---